Gabapentin
- Generic Name
- Gabapentin
- Brand Names
- Gralise, Neurontin
- Drug Type
- Small Molecule
- Chemical Formula
- C9H17NO2
- CAS Number
- 60142-96-3
- Unique Ingredient Identifier
- 6CW7F3G59X
- Background
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...
- Indication
In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...
- Associated Conditions
- Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
- Associated Therapies
- -
Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- University of Puerto Rico
- Target Recruit Count
- 100
- Registration Number
- NCT05413902
- Locations
- 🇵🇷
Puerto Rico Medical Center - University District Hospital, San Juan, Puerto Rico
Effect of Milnacipran / Gabapentin in Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 75
- Registration Number
- NCT05384210
- Locations
- 🇪🇬
Mansoura University, Mansoura, DK, Egypt
Feasibility of Early Gabapentin as an Intervention for Neurorecovery
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- MetroHealth Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT05302999
- Locations
- 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
Botulinum Toxin Type A in Diabetic Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 30
- Registration Number
- NCT05296759
- Locations
- 🇪🇬
faculty of medicine Alexandria university, Alexandria, Egypt
Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 20
- Registration Number
- NCT05172570
- Locations
- 🇺🇸
indiana University, Indianapolis, Indiana, United States
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Natalie Lockney
- Target Recruit Count
- 64
- Registration Number
- NCT05156060
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05100160
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 188
- Registration Number
- NCT05076110
- Locations
- 🇺🇸
Mayo clinic, Rochester, Minnesota, United States
Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- David Cochran
- Target Recruit Count
- 40
- Registration Number
- NCT05063656
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 68
- Registration Number
- NCT05064319
- Locations
- 🇺🇸
Medical University Of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.